Stock Events

Stock Events

Alterity Therapeutics 

$0.4000
34
+$0.05+14.29% Wednesday 17:30

Statistics

Day High
0.4
Day Low
0.4
52W High
0.5501
52W Low
0.0002
Volume
2,500
Avg. Volume
158
Mkt Cap
7.28M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

28AugExpected
Q3 2023
Q4 2023
Q2 2024
Q4 2024
Q2 2025
Q4 2025
Q2 2026
-0.04
-0.03
-0.01
-0
Expected EPS
-0.012788188227918638
Actual EPS
-0.0055339344942881025

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-7.71MNet Income

Analyst Ratings

12.67Average Price Target
The highest estimate is 16.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PRNAF. It's not an investment recommendation.
Apple
5
AAPL
Tesla
4
TSLA
Amazon
4
AMZN
Microsoft
3
MSFT

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap32.28B
Biogen focuses on neurodegenerative diseases, directly competing with Alterity's focus on Parkinson's and Alzheimer's.
Palatin Technologies
PTN
Mkt Cap18.65M
Palatin Technologies works on novel therapeutics for diseases with a significant unmet medical need, including neurological disorders.
Acadia Pharmaceuticals
ACAD
Mkt Cap5.02B
Acadia Pharmaceuticals specializes in central nervous system disorders, making it a direct competitor in the neurodegenerative disease space.
AnaptysBio
ANAB
Mkt Cap1.67B
AnaptysBio is involved in developing therapeutic antibodies, potentially competing in the neurodegenerative disease treatment market.
Anavex Life Sciences
AVXL
Mkt Cap277.16M
Anavex Life Sciences Corp. focuses on developing drugs for Alzheimer's disease and other central nervous system diseases.
Axsome Therapeutics
AXSM
Mkt Cap10.42B
Axsome Therapeutics develops therapies for central nervous system disorders, including Alzheimer's, directly competing with Alterity.
Ionis Pharmaceuticals
IONS
Mkt Cap10.15B
Ionis Pharmaceuticals develops RNA-targeted therapeutics, including for neurological disorders, competing in the same space as Alterity.
Prothena
PRTA
Mkt Cap478.97M
Prothena Corporation is focused on the discovery and development of novel antibodies for neurodegenerative diseases.
Voyager Therapeutics
VYGR
Mkt Cap218.13M
Voyager Therapeutics focuses on severe neurological diseases through gene therapy, competing in the broader neurodegenerative treatment market.

About

Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on neurodegenerative diseases and the creation of a chemical library of proprietary molecules. Its research and clinical development efforts are focused on Parkinson's disease and related disorders, where it is identifying and developing novel compounds that address the underlying pathology of these disorders by binding and redistributing excess labile iron, reducing alpha-synuclein aggregation, and rescuing neurons in the brain. Its pipeline programs are ATH434-201, ATH434-202, bioMUSE, ATH434, and Drug Discovery. The Group operated in one segment, research and development into Parkinsonian and other neurodegenerative disorders.
Show more...
CEO
David A. Stamler
Employees
9
Country
Australia
ISIN
AU0000043945
WKN
000A2PHDZ

Listings

AU
AU
ATH.AU
MU
DE
PBNN.MU
STU
DE
PBN.STU
STU
DE
PBN0.STU

0 Comments

Share your thoughts

FAQ

What is Alterity Therapeutics stock price today?▼
The current price of PRNAF is $0.40 USD — it has increased by +14.29% in the past 24 hours. Watch Alterity Therapeutics stock price performance more closely on the chart.
What is Alterity Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Alterity Therapeutics stocks are traded under the ticker PRNAF.
Is Alterity Therapeutics stock price growing?▼
PRNAF stock has risen by +0% compared to the previous week, the month change is a +14.29% rise, over the last year Alterity Therapeutics has showed a +13,233.33% increase.
What is Alterity Therapeutics market cap?▼
Today Alterity Therapeutics has the market capitalization of 7.28M
When is the next Alterity Therapeutics earnings date?▼
Alterity Therapeutics is going to release the next earnings report on March 04, 2027.
What were Alterity Therapeutics earnings last quarter?▼
PRNAF earnings for the last quarter are -0 USD per share, whereas the estimation was -0.01 USD resulting in a +56.73% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Alterity Therapeutics revenue for the last year?▼
Alterity Therapeutics revenue for the last year amounts to 0 USD.
What is Alterity Therapeutics net income for the last year?▼
PRNAF net income for the last year is -7.71M USD.
How many employees does Alterity Therapeutics have?▼
As of September 05, 2026, the company has 9 employees.
In which sector is Alterity Therapeutics located?▼
Alterity Therapeutics operates in the Health & Wellness sector.
When did Alterity Therapeutics complete a stock split?▼
The last stock split for Alterity Therapeutics was on June 03, 2026 with a ratio of 1:50.
Where is Alterity Therapeutics headquartered?▼
Alterity Therapeutics is headquartered in Melbourne, Australia.